Prostaglandin M

Prostaglandin m is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 168 references associated with Prostaglandin M in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for Prostaglandin M

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Prostaglandin M

MeSH term MeSH ID Detail
Lung Neoplasms D008175 171 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Adenomatous Polyposis Coli D011125 16 associated lipids
Osteoarthropathy, Primary Hypertrophic D010004 1 associated lipids
Total 4

All references with Prostaglandin M

Download all related citations
Per page 10 20 50 | Total 37
Authors Title Published Journal PubMed Link
Kekatpure VD et al. Elevated Levels of Urinary PGE-M Are Found in Tobacco Users and Indicate a Poor Prognosis for Oral Squamous Cell Carcinoma Patients. 2016 Cancer Prev Res (Phila) pmid:27045033
Edelman MJ et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. 2015 J. Clin. Oncol. pmid:25452446
Bezawada N et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. 2014 Cancer Prev Res (Phila) pmid:24824037
Gitlitz BJ et al. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. 2014 J Thorac Oncol pmid:24736085
Cheng R et al. Three novel mutations in the SLCO2A1 gene in two Chinese families with primary hypertrophic osteoarthropathy. 2013 Sep-Oct Eur J Dermatol pmid:24153155
Mohebati A et al. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. 2013 Cancer Prev Res (Phila) pmid:23682075
Morris PG et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. 2013 Cancer Prev Res (Phila) pmid:23531446
Zhang Z et al. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. 2013 J. Clin. Endocrinol. Metab. pmid:23509104
Shrubsole MJ et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. 2012 Cancer Prev Res (Phila) pmid:22166248
Reckamp K et al. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. 2011 Cancer pmid:20922800

Table of Content